Last updated: July 29, 2026
AMRING PHARMACEUTICALS INC v. RUBICON RESEARCH PRIVATE LTD. (2:23-cv-03494) Litigation Summary, Claims, Timeline, and Risk Analysis
Executive summary
- Case: Amring Pharmaceuticals Inc. v. Rubicon Research Private Ltd.
- Docket: 2:23-cv-03494
- Core issue: Patent infringement challenge tied to Rubicon’s FDA regulatory submission for a product associated with Amring’s asserted IP (the litigation posture aligns with a Hatch-Waxman style infringement case, typically brought after a generic or 505(b)(2) filing).
- Business impact: The case is a potential launch-blocker and a negotiation driver for licensing, design-around, and settlement. Outcome determines whether Rubicon’s proposed product can enter the market before the asserted patents (and any exclusivities) expire.
No substantive claims, asserted patents, parties’ filings, schedules, or court orders are provided in the input. Without those case-specific documents, an accurate litigation merits summary, claim construction analysis, and infringement/invalidity framework cannot be produced.
What patents are asserted in Amring Pharmaceuticals v. Rubicon Research Private Ltd. (2:23-cv-03494)?
Featured snippet answer: Not determinable from the provided information.
Which patent numbers and expiration dates matter?
- Not determinable from the provided information.
What is the asserted product and formulation strength?
- Not determinable from the provided information.
How do the asserted claims map to the generic’s ANDA 505(b)(2) submission?
- Not determinable from the provided information.
What is the procedural posture in 2:23-cv-03494 (motions, scheduling, Markman, discovery)?
Featured snippet answer: Not determinable from the provided information.
Has a temporary restraining order or preliminary injunction been sought?
- Not determinable from the provided information.
Has there been a motion to dismiss or transfer?
- Not determinable from the provided information.
Has claim construction (Markman) occurred?
- Not determinable from the provided information.
What deadlines control trial and settlement leverage?
- Not determinable from the provided information.
What is the infringement theory in the lawsuit (literal infringement, doctrine of equivalents, process claims)?
Featured snippet answer: Not determinable from the provided information.
Does Amring plead method-of-use or product-by-process claims?
- Not determinable from the provided information.
What is the likely equivalence and non-infringement dispute structure?
- Not determinable from the provided information.
How are the patents being challenged (invalidity grounds like 102/103/112 and unenforceability)?
Featured snippet answer: Not determinable from the provided information.
Is there a Section 112 enablement or written description issue?
- Not determinable from the provided information.
Is there a best mode or indefiniteness challenge?
- Not determinable from the provided information.
Is inequitable conduct or laches pleaded?
- Not determinable from the provided information.
What Paragraph IV and Orange Book triggers underlie 2:23-cv-03494?
Featured snippet answer: Not determinable from the provided information.
Which FDA application type is implicated (ANDA vs 505(b)(2))?
- Not determinable from the provided information.
What listing and certification are involved (P-IV, carve-out, non-infringement vs invalidity)?
- Not determinable from the provided information.
What is the exclusivity and patent “countdown” risk?
- Not determinable from the provided information.
When does the case matter for market entry (automatic stay and 30-month stay exposure)?
Featured snippet answer: Not determinable from the provided information.
Is a 30-month stay triggered and has it elapsed or been lifted?
- Not determinable from the provided information.
Do any listed patents expire during the litigation window?
- Not determinable from the provided information.
What settlements, consent judgments, or dismissal events occurred in Amring vs Rubicon?
Featured snippet answer: Not determinable from the provided information.
Is there a license agreement timeline or product launch commitment?
- Not determinable from the provided information.
Are there covenants not to sue, stipulations, or dismissal-with-prejudice entries?
- Not determinable from the provided information.
How strong is the patent estate for Amring in this dispute?
Featured snippet answer: Not determinable from the provided information.
How many patents are in the asserted stack and what claim breadth signals exist?
- Not determinable from the provided information.
Has the patent family been litigated previously or survived IPR/appeals?
- Not determinable from the provided information.
What generic entry risks exist for Rubicon and how does design-around affect them?
Featured snippet answer: Not determinable from the provided information.
Could Rubicon avoid infringement by changing formulation, route, or process?
- Not determinable from the provided information.
Are there formulation or method-of-use barriers that limit workarounds?
- Not determinable from the provided information.
How does this case compare with other Hatch-Waxman patent litigations by Amring or against Rubicon?
Featured snippet answer: Not determinable from the provided information.
Is the pattern consistent with Rubicon’s prior Paragraph IV challenges?
- Not determinable from the provided information.
Does Amring litigate the same patent families across multiple defendants?
- Not determinable from the provided information.
Commercial impact: what is the revenue exposure if Rubicon launches and patents fall?
Featured snippet answer: Not determinable from the provided information.
What are the potential damages theories and market share assumptions?
- Not determinable from the provided information.
Does the case affect sole-source supply, hospital contracts, or tender pipelines?
- Not determinable from the provided information.
Key Takeaways
- The docket 2:23-cv-03494 is identified, but case-specific litigation substance (asserted patents, claims, certifications, motions, and orders) is not provided, so a factual litigation summary and legal analysis cannot be completed accurately.
- Without the complaint, answer, claim chart, infringement/invalidity contentions, and docket orders, any analysis of merits, claim scope, or expected outcomes would be speculative.
FAQs
- What claims does Amring allege in 2:23-cv-03494?
- Which patents and Orange Book listings are at issue in Amring v. Rubicon?
- Has the court issued any injunction, stay, or case management orders in this docket?
- What certifications (Paragraph IV, carve-out, non-infringement, invalidity) did Rubicon file?
- Is there any reported settlement or dismissal in Amring Pharmaceuticals v. Rubicon Research Private Ltd.?
References (APA)
- No cited sources provided in the input.
